Skip to main content
AKTX
NASDAQ Life Sciences

Akari Therapeutics Files S-1 for Highly Dilutive Equity Offering to Raise Up to $7.78M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$6
Mkt Cap
$7.447M
52W Low
$3.25
52W High
$56.8
52W Position info
85% above low
Off High info
89% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AKTX sits 85% above its 52-week low of $3.25 on light trading volume (0.1× avg).

Summary

Akari Therapeutics Plc filed an S-1 registration statement for a "best-efforts" offering of ADSs and warrants, aiming to raise up to $7.78 million, which represents a substantial portion of its current market capitalization and could lead to significant dilution.


Key Events · Financing and Capital Events · AKTX

  • Equity Offering Registration

    Akari Therapeutics registered a "best-efforts" offering of up to 1,139,818 American Depositary Shares (ADSs), along with Series H Warrants, Series I Warrants, and Pre-Funded Warrants, plus 34,195 Placement Agent Warrants.

  • Significant Capital Raise

    The maximum aggregate offering price is estimated at $7.78 million, a substantial amount relative to the company's current market capitalization.

  • High Dilution Potential

    The offering could result in over 123.9% dilution from the direct ADS sale and over 400% dilution if all associated warrants are exercised, significantly impacting existing shareholders. New investors face an immediate and substantial dilution of approximately $9.83 per ADS in net tangible book value.

  • Use of Proceeds

    Funds are earmarked for research and development activities, working capital, and general corporate purposes, critical for extending the company's operational runway.


Analysis · AKTX · Life Sciences

This S-1 filing outlines a critical capital raise for Akari Therapeutics, a company with a history of operating losses and a stated need for substantial additional capital. The offering, structured as a "best-efforts" sale of ADSs, pre-funded warrants, and common warrants, seeks to raise up to $7.78 million. This amount is over 100% of the company's current market capitalization, indicating a highly dilutive event. The filing explicitly warns of "immediate and substantial dilution" to new investors, with potential dilution from the offering and full exercise of all associated warrants exceeding 400% of current outstanding ADSs. While the assumed offering price of $6.58 was based on the prior day's closing price, the filing notes the actual price could be at a discount to the then current market price. The "best-efforts" nature of the offering also introduces uncertainty regarding the total capital that will be raised, which is intended for R&D and general corporate purposes. This financing is crucial for the company's operational runway, as it currently estimates existing cash to fund operations only through mid-2027, following recent positive news about Australian patent approval for its PH1 RNA splicing modulator AD.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKTX was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $3.25 to $56.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKTX - Latest Insights

AKTX
Aug 18, 2026, 8:56 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.79
Real-time Price: $7.20 info
Change: -$0.590 (-8%) info
Market Cap: $13.408M info
AKTX
Aug 13, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $7.20 info
Change: +$0.200 (+3%) info
Market Cap: $13.408M info
AKTX
Aug 13, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $7.20 info
Change: +$0.200 (+3%) info
Market Cap: $13.408M info
AKTX
Jul 08, 2026, 4:15 PM EDT
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $14.21
Real-time Price: $7.20 info
Change: -$7.01 (-49%) info
Market Cap: $13.408M info
AKTX
Jul 02, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.41
Real-time Price: $7.20 info
Change: -$3.21 (-31%) info
Market Cap: $13.408M info